HR Execs on the Move

Benedictine Health System

www.bhshealth.org

 
Assisted Living *Skilled Nursing* Short-term rehab* The Benedictine Health System is one of the largest Catholic senior living organizations in the country, operating more than 35 communities in five states. BHS is a mission-based, non-profit health system headquartered in Minnesota, sponsored by the Benedictine Sisters of St. Scholastica Monastery in Duluth. BHS provides complete senior living and care services for aging adults, including independent housing, assisted living, long-term skilled nursing care, short-term rehabilitation and memory care. Mission The Benedictine Health System is a Catholic, faith-based organization entrusted with advancing the life-enhancing senior care ministry of the Benedictine Sisters of Duluth, ...
  • Number of Employees: 1K-5K
  • Annual Revenue: $250-500 Million

Executives

Name Title Contact Details
Ron Frei
 Regional CFO Profile
Becky Urbanski
 Sr. Vice President, Mission, Education & Marketing Communications Profile
Patricia Nott
 Vice President of People Development Profile
Patricia Nott
 Senior Vice President of People Development Profile

Similar Companies

Development Centers Inc

Development Centers Inc is a Detroit, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Binson's Home Health Care Centers

Binson's Home Health Care Centers is a Center Line, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Endocare

Endocare is one of the leading companies in Healthcare, Pharmaceuticals, & Biotech industry. Endocare is based in Irvine, CA. You can find more information on Endocare at www.endocare.com

Bioform Medical

Bioform Medical is a San Mateo, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

KaloBios

KaloBios is a biopharmaceutical company dedicated to helping the lives of patients with innovative therapies. Our mission is to improve the lives of cancer patients with innovative, Humaneered®, monoclonal antibodies. KaloBios` Humaneered® antibodies are next generation, customized antibodies designed to overcome challenges limiting today`s marketed antibody products. Using our expertise, our antibodies are customized to enhance a desired effect or reduce a possible undesired effect. Our pipeline is comprised of Humaneered® antibodies. These antibodies are being investigated in clinical development programs focused on treating cancer: KB004 (anti-EphA3) Humaneered® mAb to treat patients with hematologic malignancies, solid tumors, and their stem cells; currently enrolling patients with myelofibrosis and myelodysplastic syndrome in the company’s Phase 2 expansion portion of its Phase 1/2 clinical trial in hematologic malignancies; and KB003 (anti-GM-CSF) Humaneered® mAb that KaloBios intends to evaluate in oncology indications where GM-CSF may play a key role in such indications as chronic myelomonocytic leukemia (CMML). KaloBios intends to commence clinical evaluation of KB003 in this patient population beginning in the second half of 2015. We use a patient-targeted approach utilizing or developing a screen or diagnostic method to identify those patients most likely to benefit from our treatments.